Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3β to suppress mTOR and β-catenin signaling pathways.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Letters

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.canlet.2015.09.018PMID 26454215
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase

  2015cited by this paper
• DNA methylome analysis identifies epigenetic silencing of FHIT as a determining factor for radiosensitivity in oral cancer: an outcome-predicting and treatment-implicating study

  2014cited by this paper
• Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma

  2014cited by this paper
• Emerging role of the β-catenin-PPARγ axis in the pathogenesis of colorectal cancer.

  2014cited by this paper
• Cyproheptadine‐induced myeloma cell apoptosis is associated with inhibition of the PI3K/AKT signaling

  2013cited by this paper
• Constitutive β-catenin activation induces male-specific tumorigenesis in the bladder urothelium.

  2013cited by this paper
• Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study

  2012cited by this paper
• Emerging Roles of Angiopoietin-like 4 in Human Cancer

  2012cited by this paper
• A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.

  2012cited by this paper
• Glycogen Synthase Kinase-3β: A Prognostic Marker and a Potential Therapeutic Target in Human Bladder Cancer

  2010cited by this paper
• Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway

  2010cited by this paper
• Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors

  2010cited by this paper
• Wnt/beta-catenin signaling: components, mechanisms, and diseases.

  2009cited by this paper
• Akt-dependent and -independent mechanisms of mTOR regulation in cancer.

  2009cited by this paper
• Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer

  2009cited by this paper
• The anti‐histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor

  2009cited by this paper
• p21 in cancer: intricate networks and multiple activities

  2009cited by this paper
• Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk.

  2009cited by this paper
• PI3K pathway alterations in cancer: variations on a theme

  2008cited by this paper
• Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

  2008cited by this paper
• Cyproheptadine displays preclinical activity in myeloma and leukemia.

  2008cited by this paper
• Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.

  2008cited by this paper
• Serotonin used as prognostic marker of urological tumors

  2008cited by this paper
• HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation.

  2007cited by this paper
• Functional Interaction between Peroxisome Proliferator-Activated Receptor γ and β-Catenin

  2006cited by this paper
• Molecular Mechanism of Adaphostin-mediated G1 Arrest in Prostate Cancer (PC-3) Cells

  2006cited by this paper
• The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation

  2006cited by this paper
• TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.

  2006cited by this paper
• Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness

  2006cited by this paper
• Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin.

  2006cited by this paper
• The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells.

  2005cited by this paper
• Cell cycle and apoptosis

  2003cited by this paper
• Control of -Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism

  2002cited by this paper
• Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway.

  2002cited by this paper
• The Proto-oncogene c-myc Acts through the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kip1to Facilitate the Activation of Cdk4/6 and Early G1Phase Progression*

  2002cited by this paper
• Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism.

  2002cited by this paper
• Regulation of translation initiation by FRAP/mTOR.

  2001cited by this paper
• TOR, a central controller of cell growth.

  2000cited by this paper
• Peroxisome Proliferator-Activated Receptor γ Target Gene Encoding a Novel Angiopoietin-Related Protein Associated with Adipose Differentiation

  2000cited by this paper
• A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis.

  2000cited by this paper
• Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex.

  1999cited by this paper
• Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.

  1999cited by this paper
• β-Catenin regulates expression of cyclin D1 in colon carcinoma cells

  1999cited by this paper
• The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.

  1999cited by this paper
• Treatment of the serotonin syndrome with cyproheptadine.

  1998cited by this paper
• Synthesis, affinity at 5-HT2A, 5-HT2B and 5-HT2C serotonin receptors and structure-activity relationships of a series of cyproheptadine analogues.

  1997cited by this paper
• Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation.

  1997cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

  1993cited by this paper
• Phosphorylation of the retinoblastoma protein by cdk2.

  1992cited by this paper
• A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia

  1990cited by this paper
• A comparison of the antipruritic efficacy of hydroxyzine and cyproheptadine in children with atopic dermatitis.

  1980cited by this paper
• A comparison of the antipruritic efficacy of hydroxyzine and cyproheptadine in children with atopic dermatitis.

  1980cited by this paper

• Butyrylcholinesterase inhibitory activities of H1-antihistamines: In vitro, SAR, in silico, MD simulations, flow cytometry analysis and DNA docking studies

  2025cites this paper
• Epigenetic modulation elicits an NK cell-mediated immune response in urothelial carcinoma

  2025cites this paper
• Cancer and neurotransmitter receptors

  2025cites this paper
• Enhanced tumor suppressive effect of a new HDAC inhibitor in bladder cancer in vitro and in vivo.

  2025cites this paper
• Unlocking the Potential: Antihistamine Use and Breast Cancer Risk in Women With Type 2 Diabetes Mellitus.

  2025cites this paper
• Repositioning serotonergic antagonists as therapeutic agents in gastric cancer: induction of apoptosis, inhibition of cell migration, and cell cycle arrest in AGS cells

  2025cites this paper
• Angiopoietin-like 4 exacerbates renal tubular epithelial cell pyroptosis in acute kidney injury via integrin β5/FAK signaling pathway.

  2025cites this paper
• Overexpression of BMAL-1 is related to progression of urothelial carcinoma in arsenic exposure area

  2024cites this paper
• Emerging roles of angiopoietin-like 4 in human tumors (Review)

  2024cites this paper
• Pharmacokinetics of cyproheptadine hydrochloride in mice and beagle dogs, tissue distribution, and excretion properties of cyproheptadine hydrochloride in mice

  2024cites this paper
• Cyproheptadine inhibits in vitro and in vivo lung metastasis and drives metabolic rewiring

  2024cites this paper
• Antihistamines H1 use on survival outcomes in esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy.

  2023cites this paper
• Association of Antihistamine Use with Increased Risk of Esophageal Squamous Cell Carcinoma: A Nationwide, Long-Term Follow-Up Study Using Propensity Score Matching

  2023cites this paper
• Novel Anticancer Strategy by Targeting the Gut Microbial Neurotransmitter Signaling to Overcome Immunotherapy Resistance

  2022cites this paper
• Targeting Autophagy-Related Epigenetic Regulators for Cancer Drug Discovery.

  2021cites this paper
• Cyproheptadine causes apoptosis and decreases inflammation by disrupting thiol/disulfide balance and enhancing the levels of SIRT1 in C6 glioblastoma cells.

  2021cites this paper
• Prediction of Synergistic Drug Combinations for Prostate Cancer by Transcriptomic and Network Characteristics

  2021cites this paper
• Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma

  2021cites this paper
• OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs

  2021cites this paper
• Efficacy of Cyproheptadine Monotherapy in Hepatocellular Carcinoma With Bone Metastasis: A Case Report

  2021cites this paper
• Analysis of the effects of cyproheptadine on bladder cancer through big data.

  2020cites this paper
• Tropisetron attenuates tumor growth and progression in an experimental model of mouse lung cancer

  2020cites this paper
• Neurotransmitters: emerging targets in cancer

  2019cites this paper
• Higher Expression of Linc00152 Promotes Bladder Cancer Proliferation and Metastasis by Activating the Wnt/β-Catenin Signaling Pathway

  2019cites this paper
• TFAP4 Promotes Hepatocellular Carcinoma Invasion and Metastasis via Activating the PI3K/AKT Signaling Pathway

  2019cites this paper
• Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment

  2018cites this paper
• Circular RNA BCRC-3 suppresses bladder cancer proliferation through miR-182-5p/p27 axis

  2018cites this paper
• AP4 modulated by the PI3K/AKT pathway promotes prostate cancer proliferation and metastasis of prostate cancer via upregulating L-plastin

  2017influential citation
• Cyproheptadine use in hepatocellular carcinoma.

  2017cites this paper
• The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models

  2017cites this paper
• Ursolic acid inhibits proliferation and induces apoptosis by inactivating Wnt/β-catenin signaling in human osteosarcoma cells.

  2016cites this paper
• Tumor cell vascular mimicry: Novel targeting opportunity in melanoma.

  2016cites this paper
• Metformin and Ara-a Effectively Suppress Brain Cancer by Targeting Cancer Stem/Progenitor Cells

  2015cites this paper